Prevention of resistance: a goal for dose selection for antimicrobial agents.

Drug-resistant microorganisms have become a major problem around the world. In nosocomial and community settings, many important pathogens have demonstrated high-grade resistance to many of our most important agents. In addition, the adverse impact of resistance has not been limited to the bacterial realm. In chemotherapy to treat human immunodeficiency virus (HIV) and other viral diseases, resistance has become a major problem. We are starting to see the beginnings of a resistance problem, even among fungi. Strangely, little attention has been focused on the impact of dosing on the probability with which emergence of resistance occurs. After delineation of the pharmacodynamically linked variable, it is possible to generate dosing regimens that can lower the probability of resistance. In addition, circumstances exist in which combination therapy may be required (e.g., therapy of HIV and tuberculosis). Here, too, it is possible to optimize therapy to prevent resistance by understanding how the drugs in the regimen interact. We can do better with our choices of dose, schedule, and combinations of agents. We will need to lower the probability of resistance and maintain the utility of the drugs currently in our therapeutic armamentarium.

[1]  P. Markham.  Inhibition of the Emergence of Ciprofloxacin Resistance in Streptococcus pneumoniae by the Multidrug Efflux Inhibitor Reserpine , 1999, Antimicrobial Agents and Chemotherapy.

[2]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[3]  M. J. Lynch,et al.  Emergence of resistance to imipenem in Pseudomonas aeruginosa , 1987, Antimicrobial Agents and Chemotherapy.

[4]  Ronald N. Jones,et al.  Antibacterial activity of 41 antimicrobials tested against over 2773 bacterial isolates from hospitalized patients with pneumonia: I--results from the SENTRY Antimicrobial Surveillance Program (North America, 1998). , 2001, Diagnostic microbiology and infectious disease.

[5]  J. Bilello,et al.  Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. , 1998, The Journal of infectious diseases.

[6]  J. Quinn,et al.  Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. , 1986, The Journal of infectious diseases.

[7]  M. Wolin,et al.  In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus , 1997, Antimicrobial agents and chemotherapy.

[8]  Jerome J. Schentag,et al.  Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. , 1989, Archives of internal medicine.

[9]  Jerome J. Schentag,et al.  Pharmacodynamic Evaluation of Factors Associated with the Development of Bacterial Resistance in Acutely Ill Patients during Therapy , 1998, Antimicrobial Agents and Chemotherapy.

[10]  J. Bilello,et al.  The Triple Combination Indinavir-Zidovudine-Lamivudine Is Highly Synergistic , 2000, Antimicrobial Agents and Chemotherapy.

[11]  G. Drusano,et al.  Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint , 2001, Antimicrobial Agents and Chemotherapy.

[12]  H. Chambers,et al.  The changing epidemiology of Staphylococcus aureus? , 2001, Emerging infectious diseases.

[13]  D E Low,et al.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. , 1999, The New England journal of medicine.

[14]  J. Kahn,et al.  Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.

[15]  W. Craig,et al.  The pharmacology of meropenem, a new carbapenem antibiotic. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  C. Crumpacker,et al.  Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. , 1989, The New England journal of medicine.

[17]  J. Lopez-Ribot,et al.  Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients , 2001, Antimicrobial Agents and Chemotherapy.

[18]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[19]  S. Chou.  Antiviral drug resistance in human cytomegalovirus , 1999, Transplant infectious disease : an official journal of the Transplantation Society.

[20]  D M Grasela,et al.  The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. , 2000, Diagnostic microbiology and infectious disease.

[21]  Susan R. Johnson,et al.  Macrolide Resistance among Invasive Streptococcus Pneumoniae Isolates , 2022 .